Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05280509 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 21, 2023 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 14 to 19v8
  2. Study sites: 12 to 14v7
  3. Study sites: 5 to 12
    • Start date changed from estimate of Oct 2022 to Jun 9, 2022
    v6
  4. Study sites: 1 to 5v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Trial Details
NCT Number NCT05280509
Lead Sponsor Telios Pharma, Inc.
Conditions
(from sponsor)		 Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Related terms Primary Myelofibrosis
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov